Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL

Lucid Diligence Brief: Disc Medicine bitopertin FDA CRL Professional audiences…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership

Lucid Diligence Brief: Ubie and Mayo Clinic's digital front door partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH

Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for pertussis vax

Lucid Diligence Brief: ILiAD Biotechnologies $115 million Series B for…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis

Lucid Diligence Brief: Nektar's REZPEG in atopic dermatitis Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to MeiraGTx

Lucid Diligence Brief: ZipBio licenses its AI-designed GA AAV program to…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen

Lucid Diligence Brief: Kyowa Kirin regains rocatinlimab rights from Amgen…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration

Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD

Lucid Diligence Brief: Boehringer Ingelheim and Simcere partner in IBD…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb collaboration

Lucid Diligence Brief: Janux Therapeutics and Bristol Myers Squibb…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: GSK to acquire RAPT Therapeutics

Lucid Diligence Brief: GSK to acquire RAPT Therapeutics Professional audiences…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T

Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…


Privacy Preference Center